© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Ligand Pharmaceuticals Incorporated (LGND) shows an Average True Range (ATR) of 6.63 and an Enterprise Value of 1.24B. Its average trading volume over the past 3 months is 190.81K, indicating liquidity. These fundamental metrics provide insight into LGND's underlying financial health and market activity.
Ligand Pharmaceuticals Incorporated (LGND) technical indicators as of December 23, 2025: the SMA 20 is 1.98%, SMA 50 at 2.23%, and SMA 200 at 36.51%. The RSI 14 value is 55.52, suggesting its current momentum. These technical analysis signals help assess LGND's price trends and potential future movements.
Ligand Pharmaceuticals Incorporated (LGND) stock performance overview as of December 23, 2025: The 52-week high is $212.49 (currently -6.84% below), and the 52-week low is $93.58 (currently 111.54% above). Over the past year, LGND's performance is 61.81%, compared to the S&P 500's 10.56% change.
According to market data, Ligand Pharmaceuticals Incorporated (LGND) stock's recent performance metrics show that over the last month, LGND is -3.93%, with a Year-to-Date (YTD) performance of 84.75%. Over the past year, the stock has seen a 61.81% change. These figures summarize LGND's price movements across various periods, reflecting its historical returns.
According to current financial data, LGND stock's P/E (TTM) ratio is 107.23, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for LGND, including P/S (15.54), P/B (4.04), and P/FCF (97.67), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.